Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 4/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761789 | 0.91 | TGFBR1 (0.44) | TGFBR1TLR7ULK1PIN1MAPK14 | |
| SCHEMBL4720079 | 0.87 | TGFBR1 (0.46) | TGFBR1CHEK1TLR7SCN9AMAPKAPK2 | |
| SCHEMBL4877485 | 0.85 | TGFBR1 (0.51) | TGFBR1TLR7KDRGSK3AGSK3B | |
| SCHEMBL4828522 | 0.83 | CHEK1 (0.40) | CHEK1TLR7SCN9AMAPKAPK2ALK | |
| SCHEMBL4868034 | 0.82 | TGFBR1 (0.49) | TGFBR1TLR7KDRMAPK14 | |
| SCHEMBL4826461 | 0.82 | CHEK1 (0.37) | CHEK1TLR7SCN9AMAPKAPK2ALK | |
| SCHEMBL4762453 | 0.81 | TGFBR1 (0.57) | TGFBR1TLR7KDRMAPK14 | |
| SCHEMBL6004210 | 0.80 | TGFBR1 (0.46) | TGFBR1TLR7SCN9AGSK3BMAPK14 | |
| SCHEMBL4761324 | 0.79 | TLR7 (0.45) | TGFBR1TLR7SCN9AMAPK14 | |
| SCHEMBL4761790 | 0.78 | TGFBR1 (0.49) | TGFBR1ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | TGFBR1 572/4885CHEK1 564/4885TLR7 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.